Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ: LEXX )

1.477 -0.003 (-0.22%)
Streaming Delayed Price Updated: 1:59 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Approval from Independent Review Board for DehydraTECH-CBD Human Clinical Study
Via Investor Brand Network
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
• Dosing is expected to begin by April, 2022 KELOWNA, BC / ACCESSWIRE / December 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Bioscience Expects Study Results to Show Patented Tech's Value in Treating Hypertension
Lexaria Bioscience is preparing to file an Investigational New Drug application with the U.S. Food and Drug Administration for its patented technology’s use in treating... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Expects Study Results to Show Patented Tech’s Value in Treating Hypertension
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expects Study Results to Show its Patented Tech’s Value in Treating Hypertension Patients
Via Investor Brand Network
Lexaria Bioscience Announces Major Discovery; Increasing Effectiveness of Orally Administered CBD
In a recent human clinical trial, HYPER-H21-2, DehydraTECH-CBD reduced arterial stiffness, potentially broadening Lexaria’s application’s ability to treat... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Announces Major Discovery; Increasing Effectiveness of Orally Administered CBD
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Major Discovery; Increasing the Effectiveness of Orally Administered CBD
Via Investor Brand Network
Lexaria Bioscience (NASDAQ: LEXX) Pursuing Regulatory Approvals for DehydraTECH(TM)
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pursuing Regulatory Approvals for DehydraTECH(TM), Entry into Different Markets
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pursuing Regulatory Approvals for DehydraTECH(TM), Entry into Different Markets
Via Investor Brand Network
Lexaria's DehydraTECH(TM) CBD Found to Reduce Arterial Stiffness in Study
Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood... 
Via Benzinga
Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM) CBD Found to Reduce Arterial Stiffness in Study
Via Investor Brand Network
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Media Agreement with SRAX Inc. (NASDAQ: SRAX)
Via Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-CBD Reduces Arterial Stiffness in Study HYPER-H21-2 Broadening Applications Beyond Hypertension
Via Investor Brand Network
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
KELOWNA, BC / ACCESSWIRE / December 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
Kelowna, British Columbia – TheNewswire - December 16, 2021 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms... 
Via TheNewswire.com
Lexaria Bioscience Committed to Innovation and Improving Quality of Life
Lexaria presented at this year’s Benzinga Global Small Cap Conference held on December 8-9, 2021 The event came right after the company announced human clinical... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Committed to Innovation and Improving Quality of Life
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Participates in the Benzinga Global Small Cap Conference; Committed to Innovation and Improving Quality of Life
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Results Expected to Demonstrate DehydraTECH-CBD’s Effectiveness Against Hypertension
Via Investor Brand Network
Exposures Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Results Expected to Demonstrate DehydraTECH-CBD’s Effectiveness Against Hypertension
Via CannabisNewsWire
Exposures Product Safety
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
KELOWNA, BC / ACCESSWIRE / December 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its human... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria's Upcoming R&D Programs Targeting Global Markets Exceeding $160B
Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022 The programs are designed to explore the ability of the company’s... 
Via Benzinga
Lexaria’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Exceeding $160B
Via Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Totaling Over $160 Billion
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Reshape Lifesciences (NASDAQ:RSLS... 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics
Via Investor Brand Network
52 Biggest Movers From Yesterday
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares surged 84.1% to close at $19.11 on Wednesday. Insignia Systems recently announced the commencement of a formal process to... 
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.